BusinessNewsAPI
Eli Lilly’s $3.25 billion acquisition of Kelonia Therapeutics caps startup’s tortuous ride - statnews.com
Overview
Eli Lilly is buying Kelonia Therapeutics for $3.25 billion, acquiring the small biotech’s cell therapy programs for cancer and autoimmune diseases. Kelonia had struggled as a startup, and the deal gives Lilly external capabilities in cellular medicines to complement its internal pipeline. Paired with recent clinical progress on drugs like retatrutide and Lilly’s agreement to acquire three vaccine developers, the Kelonia purchase is part of a broader M&A push to diversify into cell therapies, vaccines and other biologics beyond metabolic disease.
Entities
ORGEli LillyORGKelonia TherapeuticsORGStat News
Relationship Graph
Click a connection line between nodes to view confidence and evidence.
Nodes: 3 · Connections: 2
Caused by
Led to
Related to
Same event
Press enter or space to select a node. You can then use the arrow keys to move the node around. Press delete to remove it and escape to cancel.
Press enter or space to select an edge. You can then press delete to remove it or escape to cancel.
Click a connection for evidence · click a node to open it
Select a connection to see why these events are linked.